MetaVia Inc. MTVA
1.06 USD -0.03 (-2.75%)
As ofNov 20, 2026, 10:19 AM EST
1.05 Day range 1.10
0.966 52-week range 13.42
- YTD
- -87.41%
- 1 year
- -85.46%
News
prnewswire.com MetaVia Announces Completion of Last Patient Visit in Extended 24-Week Phase 1 Part 3A Study of DA-1726 Encouraging Preliminary Safety and Tolerability Observations in Part 3A Supported Decision to Extend Treatment from 16 to 24 Weeks Positive Part 3B Interim Data Presented at Precision Liver Symposium…benzinga.com Metavia Announces Preclinical Data From Head-To-Head Study Comparing Novel GLP-1 DA-1726 With Retatrutide; Sees Statistically Significant Increase In Liver And Circulating FGF21 Expression; Plans Phase 2 Study In MetALD And ALD H2 2027 MetaVia Inc. (NASDAQ:MTVA), a clinical-stage biotechnology company focused on transforming liver-related cardiometabolic diseases, today announced positive preclinical data from a head-to-head study…
prnewswire.com MetaVia Presents Preclinical Data Supporting the Potential of DA-1726 to Address Liver Disease and Weight Loss at ObesityWeek® 2026 Statistically Significant Increase in Liver and Circulating FGF21 Expression Greater Glucose Lowering and Comparable Weight Loss vs. Retatrutide with Less Reliance on Appetite Suppression MetaVia…benzinga.com MetaVia Q3 EPS $(0.69) Beats $(0.73) Estimate MetaVia (NASDAQ:MTVA) reported quarterly losses of $(0.69) per share which beat the analyst consensus estimate of $(0.73) by 5.48 percent. This is a 55.19 percent increase over losses of $(1.54) per…
prnewswire.com MetaVia Reports Third Quarter 2026 Financial Results and Provides Corporate Update Positive DA-1726 16-Week Phase 1 Part 3 Interim Data Support Planned Phase 2 Development in MetALD and ALD Appointed Sarah Browne, M.D., as Chief Medical Officer to Help Lead the Next Stage of…
benzinga.com MetaVia's Potential Drug Candidate Cuts Serum Uric Acid and Liver Fat MetaVia reports positive Phase 1 data showing that once-weekly DA-1726 significantly reduces serum uric acid and liver fat.benzinga.com MetaVia Announces Interim Data From Part 3B Of Its Phase 1 Clinical Trial Of DA-1726 Targeting Both GLP-1 And Glucagon Receptors; Results Demonstrate 68% Placebo-Adjusted Reduction In Liver Fat And 13.5% Placebo-Adjusted Body Weight Reduction Following 16 Weeks Of Once-Weekly DA-1726 Treatment In Otherwise Healthy Adults With Obesity; Plans Phase 2 For H2 2027 At Day 109, 10 of 12 DA-1726-treated participants (83%) in the MRI substudy achieved a relative liver fat reduction of at least 30%, compared with none on placebo. All DA-1726-treated participants…
benzinga.com MetaVia To Report Data From Its Phase 1 Clinical Study Of DA-1726 At Precision Liver Symposium 2026 MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that an abstract highlighting data from the Phase 1 clinical…
benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session Gainers Senti Biosciences (NASDAQ:SNTI) stock rose 51.8% to $0.27 during Monday's after-market session. The company's market cap stands at $5.9 million. Polyrizon (NASDAQ:PLRZ) shares increased by…
